• Products
  • Community
  • Markets
  • Brokers
  • More
Get started
  • Markets
  • /World stocks
  • /Ideas
ALKEM LABORATORIES LTD S/R Support and Resistance Levels: Support Levels: These are price points (green line/shade) where a downward trend may be halted due to a concentration of buying interest. Imagine them as a safety net where buyers step in, preventing further decline. Resistance Levels: Conversely, resistance levels (red line/shade) are where upward trends might stall due to increased selling interest. They act like a ceiling where sellers come in to push prices down. Breakouts: Bullish Breakout: When the price moves above resistance, it often indicates strong buying interest and the potential for a continued uptrend. Traders may view this as a signal to buy or hold. Bearish Breakout: When the price falls below support, it can signal strong selling interest and the potential for a continued downtrend. Traders might see this as a cue to sell or avoid buying. MA Ribbon (EMA 20, EMA 50, EMA 100, EMA 200) : Above EMA: If the stock price is above the EMA, it suggests a potential uptrend or bullish momentum. Below EMA: If the stock price is below the EMA, it indicates a potential downtrend or bearish momentum. Trendline: A trendline is a straight line drawn on a chart to represent the general direction of a data point set. Uptrend Line: Drawn by connecting the lows in an upward trend. Indicates that the price is moving higher over time. Acts as a support level, where prices tend to bounce upward. Downtrend Line: Drawn by connecting the highs in a downward trend. Indicates that the price is moving lower over time. It acts as a resistance level, where prices tend to drop. Disclaimer: I am not a SEBI registered. The information provided here is for learning purposes only and should not be interpreted as financial advice. Consider the broader market context and consult with a qualified financial advisor before making investment decisions.
NSE:ALKEM
by zenthosh
LCTITAN retrace 2nd wave before SUPER 3rd waveretracement happens at 0.618 got volume spike after earnings announcement quarter loss is improving, likely will turn to black (profitable) next quarter we'll see whether will follow gann fan or not
MYX:LCTITANLong
by pengamalgelombang
ABFRL at Best Support !!This is the Weekly Chart Of ABFRL . ABFRL having good Law of Polarity at 70 range. ABFRL having EMA support at 72 range If this level is sustain , we may see higher price in ABFRL || Based on time-wise analysis, our initial expected return is 40–42%, which the stock consistently forms beyond the Law of Polarity (LOP). Thank You !!
NSE:ABFRLLong
by FiveCircles
IPO Price Respected — Now Coiling for a Major Breakout? 🔍 Chart Context & Structure Since its listing, SBI Cards & Payment Services Ltd (NSE: SBICARD) has been forming a massive accumulation base on the weekly chart — with an iron-clad support zone around ₹650. Over the last 3.5 years, the stock never closed below this IPO zone, signaling strong institutional confidence and long-term investor conviction. Now, after multiple failed attempts, price is retesting the crucial ₹930–₹972 resistance band — a level that previously triggered sharp rejections. But this time, the setup is different: ✅ Momentum is building with a consistent series of higher lows. ✅ The structure now hints at a rounding bottom formation. ✅ Volume is supportive (if visible), and sentiment around financials is shifting positive. 📊 Technical Zones to Watch Zone Relevance 🔵 ₹660–₹715 Strong base zone (IPO support + demand cluster) 🟣 ₹930–₹972 Historical supply zone (tested 3rd time now) 🟠 ₹1,130–₹1,150 Minor resistance, could break quickly post breakout 🟡 ₹1,272 – ₹1,440 Fibonacci targets (1.272–1.618 extension) 🔴 ₹1,916 Final positional target (2.618 Fib extension from pandemic low) 🌐 The Macro Tailwinds 💳 Credit card usage in India is booming – penetration is still low compared to global norms, but monthly user growth is accelerating. 🏛️ Government is actively promoting digital payments – a key pillar in India’s fintech roadmap. 📈 Financialization of Indian households – from cash hoarding to credit leverage, behavior is shifting. 🔁 Consumer spending is rebounding strongly post-COVID and SBI Cards is a direct proxy. 💡 Investor Psychology Think of the ₹930–₹972 zone like a "psychological lid". Price got rejected here twice before — so this third approach carries both hesitation and anticipation. A weekly close above this zone would likely: Trigger short-covering from swing sellers, Attract momentum traders, And validate long-term bulls waiting for confirmation. 📌 Trading Plan (Positional Swing) Entry Trigger: Weekly close above ₹972 Initial Target: ₹1,130 → ₹1,192 Medium-Term Targets: ₹1,272 → ₹1,343 → ₹1,440 Long-Term Target: ₹1,916 Stop-Loss (Weekly): Close below ₹880 Holding Period: 6 months to 2 years depending on breakout strength 🧠 Final Thought "Not closing below IPO levels for over 3 years in a volatile mid-cap is not random — it's informed accumulation." With digital payment adoption surging and tailwinds aligning, SBI Cards may be quietly entering a new phase of price discovery. Watch the ₹972 zone closely — what was resistance may soon become the launchpad.
NSE:SBICARDLong
by Anany_shringi
FFL | Inverse H&SFFL is forming Inverse Head and Shoulder Pattern on daily time frame, which a bullish reversal pattern, currently the stock is at neckline resistance upon break out and retest more upside towards 19.50 is expected.
PSX:FFLLong
by mbaberhanif
Quick View: $PYPLDaily -> Pullback after bullish crossovers of every EMA Weekly -> Still bearish with test of the price to EMA 50 Watching for a #TopSwing Setup on the Daily Chart Area of $73.5-$74.5 as key resistance. Structure is interesting, but I’m waiting for a clear signal. Support → $65
NASDAQ:PYPL
by TizyCharts
FABL | Growth Potential AheadAccording to its price action, FABL is currently trading within a corrective structure, with a strong support zone identified at 45, offering a strategic entry opportunity for long positions. The price is moving within a downward-sloping channel, indicating a consolidation phase, with a potential breakout towards higher levels. Entry Zone: Around 45 Stop Loss: Below 43 TP1: 51 TP2: 54 Risk To Reward Ration = 1 : 4.50
PSX:FABLLong
by mbaberhanif
Updated
HIMS Weekly Options Outlook — June 3, 2025📉 HIMS Weekly Options Outlook — June 3, 2025 🚨 AI Model Consensus: Moderately Bearish into June 6 Expiry 🧠 Model Overview 🔹 Grok (xAI) Bias: Neutral Setup: Bearish short-term, bullish long-term; mixed outlook Trade: No action — lacks edge Confidence: 35% 🔹 Claude (Anthropic) Bias: Moderately Bearish Setup: Below EMAs, bearish MACD; cautious sentiment Trade: Buy $52P @ $0.94 → PT $1.88+, SL $0.56 Confidence: 72% 🔹 Llama (Meta) Bias: Moderately Bearish Setup: Post-run fractal pullback, mixed but leaning down Trade: Buy $52P → PT +20%, SL −50% Confidence: 70% 🔹 Gemini (Google) Bias: Moderately Bearish Setup: Clean break under EMAs, MACD/RSI confirm weakness Trade: Buy $50P @ ~$0.47 → PT 100%, SL 50% Confidence: 65% 🔹 DeepSeek Bias: Moderately Bearish Setup: Breakdown across timeframes; skewed put flow Trade: Buy $50P @ $0.45 → PT $0.70, SL $0.32 Confidence: 65% ✅ Consensus Summary 📉 4 of 5 models recommend bearish weekly puts 🔻 Clear breakdown under EMAs with supportive MACD/RSI signals 🧲 Max Pain at $55 could cause late-week pullback or stall 🎯 Preferred strategy: OTM naked puts with high ROI potential 🎯 Recommended Trade Setup 💡 Strategy: Weekly Bearish Put Play 🔘 Ticker: HIMS 📉 Direction: PUT 🎯 Strike: $52 💵 Entry: $0.94 (ask) 🎯 Profit Target: $1.70 (+80%) 🛑 Stop Loss: $0.56 (−40%) 📏 Size: 1 contract 📅 Expiry: 2025-06-06 ⏰ Entry Timing: Market Open 📈 Confidence: 70% ⚠️ Risk Factors to Watch 🧲 Max pain at $55 could slow breakdown or cause snapback 🔻 $52 support zone may cause consolidation or chop 📉 Falling VIX = compressed premiums, slower option movement ⌛ Theta accelerates into Thursday/Friday — exit early if flat
NYSE:HIMSShort
by quantsignals
NVTS Weekly Options Outlook — June 3, 2025📉 NVTS Weekly Options Outlook — June 3, 2025 🚨 AI Consensus: Moderately Bearish into June 20 Expiry 🧠 Model Breakdown 🔹 Grok (xAI) Bias: Moderately Bearish Setup: 5-min price under 10 EMA, MACD weak; overbought daily band Trade: Buy $6.00P @ $0.70 → PT $1.05, SL if NVTS > $6.10 Confidence: 65% 🔹 Claude (Anthropic) Bias: Moderately Bearish Setup: Consolidation phase, overbought daily RSI, falling volume Trade: Buy $5.50P @ $0.45 → PT $0.70–$0.95, SL $0.25 Confidence: 65% 🔹 Llama (Meta) Bias: Moderately Bearish Setup: RSI ~41, bearish MACD; still long-term bullish Trade: Buy $5.50P @ $0.45 → PT +50%, SL if NVTS > $6.20 Confidence: 65% 🔹 Gemini (Google) Bias: Moderately Bearish Setup: Rally fading, MACD histogram decaying Trade: Buy $6.00P @ $0.70 → PT $1.05, SL $0.49 Confidence: 65% 🔹 DeepSeek Bias: Moderately Bullish (Contrarian) Setup: Daily trend strong; news catalysts could lift price Trade: Buy $6.00C @ $0.70 → PT $1.00, SL $0.45 Confidence: 70% ✅ Consensus Summary ✅ Recent rally is cooling across all models (overbought RSI, fading MACD) 🧲 Max pain @ $5.50 = gravitational pull risk 📉 4 of 5 models recommend buying puts 📊 Two preferred strikes: $5.50P (Llama/Claude), $6.00P (Grok/Gemini) 📈 DeepSeek remains bullish due to news catalysts 🎯 Recommended Trade Setup 💡 Strategy: Bearish Naked Weekly Put 🔘 Ticker: NVTS 📉 Direction: PUT 🎯 Strike: $5.50 💵 Entry: $0.45 🎯 Profit Target: $0.68 (+50%) 🛑 Stop Loss: $0.25 (−45%) 📏 Size: 1 contract 📅 Expiry: 2025-06-20 ⏰ Entry Timing: Market Open 📈 Confidence: 65% ⚠️ Key Risks to Monitor 🔼 News catalyst (Nvidia/Hydrogen) could reverse downside ⚠️ Low put liquidity may result in wide bid/ask spreads 📈 Break above $6.20 invalidates bearish setup ⌛ Theta decay quickens late next week — exit early if no move
NASDAQ:NVTSShort
by quantsignals
HOOD Weekly Options Outlook — June 3, 2025📈 HOOD Weekly Options Outlook — June 3, 2025 🚨 AI Model Consensus: Moderately Bullish Into June 6 Expiry 🧠 Model Summary 🔹 Grok (xAI) Bias: Moderately Bullish Setup: Near 10 EMA, RSI oversold (34.7), strong 5-min EMA alignment. Trade: Buy $72C @ $0.78 → PT +50%, SL −20% 🔹 Claude (Anthropic) Bias: Moderately Bearish Setup: Price below M5 10 EMA, high sell volume; RSI overbought daily. Trade: Buy $69P @ $2.63 → PT +50%, SL −30% 🔹 Llama (Meta) Bias: Moderately Bullish Setup: RSI oversold (5-min), MACD mixed; Daily RSI high. Trade: Buy $73C @ $0.60 → PT $0.90, SL $0.30 🔹 Gemini (Google) Bias: Moderately Bullish Setup: RSI oversold intraday; resistance near $73.15 Trade: Buy $74C @ $0.44 → PT $0.80–0.88, SL $0.22 or below $71 🔹 DeepSeek Bias: Moderately Bullish Setup: Oversold bounce potential in strong trend Trade: Buy $73C @ $0.60 → PT $0.90–1.20, SL $0.30 ✅ Consensus Summary 📈 Daily uptrend remains strong across all models 📉 Short-term RSI is oversold → bounce setup likely 📰 Bullish news + falling VIX = supportive backdrop 🧲 Max Pain @ $65 = caution for Friday pin 4 out of 5 models favor bullish call plays 🎯 Recommended Trade Setup 💡 Strategy: Bullish Naked Weekly Call 🔘 Ticker: HOOD 📈 Direction: CALL 🎯 Strike: $73 💵 Entry: $0.60 (limit order suggested) 🎯 Profit Target: $0.90 (+50%) 🛑 Stop Loss: $0.30 (−50%) 📏 Size: 1 contract 📅 Expiry: 2025-06-06 ⏰ Entry Timing: Market Open 📈 Confidence: 70% ⚠️ Risk Factors to Watch 📉 Daily RSI >79 = potential for broader pullback 🔄 Max Pain @ $65 could act as drag near expiration 📉 Break below $71.10 invalidates bullish thesis ⌛ Theta decay accelerates after Wednesday
NASDAQ:HOODLong
by quantsignals
AAPL Weekly Options Outlook — June 3, 2025📈 AAPL Weekly Options Outlook — June 3, 2025 🚨 AI Model Consensus: Moderately Bullish into June 6 Expiry 🧠 Model Summary 🔹 Grok (xAI) Bias: Moderately Bullish Setup: Price above EMAs, MACD divergence softening; resistance at $203.40 Trade: Buy $207.50C @ $0.67 → PT $1.00, SL if AAPL < $202 Confidence: 65% 🔹 Claude (Anthropic) Bias: Moderately Bullish Setup: Bullish reversal, rising EMAs, MACD improving Trade: Buy $207.50C @ $0.67 → PT $1.20–$1.80, SL $0.35 Confidence: 70% 🔹 Gemini (Google) Bias: Moderately Bullish Setup: Above EMAs, MACD histogram rising; resistance $203.46–$203.81 Trade: Buy $207.50C @ ~$0.65 → PT $0.97–$1.14, SL $0.32 Confidence: 65% 🔹 Llama (Meta) Bias: Moderately Bullish Setup: Above EMAs, MACD crossover building Trade: Buy $207.50C @ $0.67 → PT $0.80, SL $0.335 Confidence: 70% 🔹 DeepSeek Bias: Moderately Bearish Setup: MACD still negative; resistance at $203.81 Trade: Buy $200P @ $0.93 → PT $1.86, SL $0.46 Confidence: 65% ✅ Consensus Highlights 🔼 Bullish Momentum on short-term EMAs 📉 Max Pain at $200 could limit upside by Friday 📊 Strong liquidity on both $207.50C and $200P 🔁 Most models plan to exit midweek; only DeepSeek expects a breakdown 🎯 Recommended Trade Setup 💡 Strategy: Bullish Single-Leg Weekly Call 🔘 Ticker: AAPL 📈 Direction: CALL 🎯 Strike: $207.50 💵 Entry: $0.67 (ask) 🎯 Profit Target: $1.17 (+75%) 🛑 Stop Loss: $0.34 (−50%) 📏 Size: 1 contract 📅 Expiry: 2025-06-06 ⏰ Entry Timing: Market Open 📈 Confidence: 68% ⚠️ Risk Factors 📉 Max pain gravity could limit upside later in the week 🔼 Resistance zone at $207.50–$210 may stall momentum ⌛ Rapid theta decay — needs early move to profit 📰 Any negative macro or tech headlines could invalidate setup
NASDAQ:AAPLLong
by quantsignals
Sanofi takes a bold step by acquiring Blueprint MedicinesSanofi Makes Bold Move with $9.5 Billion Acquisition of Blueprint Medicines By Ion Jauregui – Analyst at ActivTrades French pharmaceutical giant Sanofi (EPA:SAN) has kicked off 2025 with a bold strategic move: the acquisition of U.S.-based biotech Blueprint Medicines (NASDAQ:BPMC) for up to $9.5 billion. The deal, expected to be the largest healthcare acquisition in Europe this year, includes an upfront payment of $129 per share, plus contingent value rights (CVRs) tied to the commercial success of BLU-808, a treatment for systemic mastocytosis. With this acquisition, Sanofi secures full control of Ayvakit, currently the only approved treatment for this rare disease, thereby strengthening its position in the lucrative rare diseases segment. Strong Financial Momentum in 2024 Sanofi’s latest annual results confirm the company’s solid trajectory. In 2024, the group generated €41.081 billion in revenue, representing a 11.3% increase at constant exchange rates. Adjusted net income reached €8.912 billion, up 4.1%, despite cost pressures in some segments. Flagship drug Dupixent, developed in partnership with Regeneron, brought in €13.072 billion, accounting for nearly a third of total group revenue. The vaccines segment also performed strongly, led by Beyfortus sales, with a growth of 13.5%. Favorable Market: Technical Analysis Sanofi shares have also been enjoying a positive trend. As of yesterday’s close, the stock was trading at €86.77, with a bullish pre-market and not far from its annual high of €106.20. From May to May, the stock gained as much as 47.43% year-over-year, reaching all-time highs. After the announcement of U.S. tariff policies, the stock corrected nearly 21%, but quickly recovered from a key support level at €82.51, now hovering near €87 with a positive outlook. The only technical concern lies in the bearish crossover of moving averages observed earlier this year. Should this acquisition reinforce Sanofi’s fundamentals, the resistance level around €93.70 may soon be breached and potentially become new support. Failure to do so, however, could see a short-term pullback toward €67.78. What’s clear is that the company is committed to maintaining its year-over-year growth trend and pushing for new record highs. Key technical levels: • Support: €79.80 (current point of control and mid-range zone) • Immediate resistance: €106.20 (52-week high) • RSI: 37.45 – signaling an oversold zone, possibly ready for recovery • Moving Averages: Showing a downward trend this quarter, requiring a shift to resume the bullish path From a fundamental perspective, the stock trades at an estimated P/E ratio of 12.7, which still offers value considering its earnings outlook and a solid dividend yield of 3.8%. Share Buyback and Clear Roadmap As part of its shareholder value strategy, Sanofi has launched an ambitious €5 billion share buyback program, equivalent to 4% of its capital. This move reflects management’s confidence in the company’s performance and comes amid strong cash flow generation. For 2025, Sanofi projects mid-to-high single-digit revenue growth and a low double-digit increase in adjusted net income. Conclusion: Innovation, Profitability, and Global Ambition The acquisition of Blueprint Medicines not only marks the largest healthcare deal in Europe this year, but also cements Sanofi’s strategic shift: focusing on innovative treatments, specialized markets, and global expansion. With a solid financial foundation, a technically strong stock, and a more focused product portfolio, Sanofi is emerging as a major player in the healthcare sector for 2025. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk.
EURONEXT:SANLong
by ActivTrades
SWIGGY – Rounded Bottom Breakout with Volume SurgePattern: Rounded bottom Breakout level: ₹345 Current price: ₹355.55 (+6.71%) Volume: 24.64M (above 20-day average of 20.91M) RSI: 66.27 – strong bullish momentum Target: ₹409 (18 percent upside) Stop-loss: ₹324 Invalidation: Close below ₹340 with volume Context: A well-defined rounded base has broken out with strong follow-through. Volume exceeds the average, RSI confirms momentum, and the breakout candle shows no selling pressure. A bullish divergence in RSI had already signaled accumulation before price action confirmed it. Coverage initiation by Morgan Stanley aligns with, but does not drive, the technical breakout. Disclaimer: This analysis is intended for informational and educational purposes only and does not constitute financial, investment, or trading advice. Trading and investing in equities involve risk, including the risk of capital loss. The pattern recognition and breakout setup described here are based purely on technical chart analysis, without consideration of the company’s financial statements, earnings outlook, or valuation metrics. Market conditions can change rapidly, and price targets or stop-loss levels may not be respected under volatile scenarios. Always consult your financial advisor and conduct your own due diligence before making any investment decisions.
NSE:SWIGGYLong
by eggubonda
Canadian Natural resources is undervaluedUsing my simple method of technical analysis and fundamental calculation of the intrinsic value of a stock for which the range of intrinsic value of CNQ is between $35-$55. Assuming oil can make a reversal at this pivotal time in history for the world the stock looks very cheap. It also pays good dividends soon which was a bonus I bought some at $31 dollars for the market price. It looks like a great addition to make a nicely diversified portfolio.
NYSE:CNQLong
by Capitalist_Zach
Nse listign affect ??nse listing is on cards and I see stock broking company flying high please check and do your analysis
NSE:NUVAMALong
by Nishpaul06
CARE - CUP WITH HANDLEPosition Update: May 16, 2025 Key factors: 1. Low-risk entry point. 2. Very clear bases with VCP characteristics. 3. A confirmed Stage 2 uptrend, indicating upward continuation. 4. The stock is outperforming, rising even as the broader market trends lower. 5. Displays strong relative strength against the market and peers. 6. Volume dries up suggests less supply coming to the market. 7. Many stocks start showing traction based on my own stock continuum. Considerations: While the breakout was not accompanied by a significant volume surge, this development is occurring within the early stages of what appears to be a new bull market cycle. This macro backdrop may provide additional support and follow-through potential. I’d like to see if it can hold up and follow through from here.
IDX:CARELong
by rifqonr
Updated
TEXRAIL | Buy @LTP | SL below 152 | 1st Target 200, 230Disclaimer: This is not financial advice. Please do your own research or consult with a financial advisor before making any investment decisions. Investments in stocks can be risky and may result in loss of capital.
NSE:TEXRAILLong
by ProfitLossMereSath
FortisFortis setting up nicely fr target 800+. Keep eye fr Ath.
NSE:FORTISLong
by hrishikamirwani
The 3 Step Rocket Booster StrategyOn this trade we are looking at the NASDAQ:AMZN trade.Now the special thing about this trade is that instead of focusing on the daily chart we are focusing on the weekly chart. You may be thinking “Why are we focusing on the weekly chart?” Well this is because you have to be ahead of the crowd nd see the coming trend. If you want to do your own trading strategy thats okay but if you want to learn more about the Rokcet booster strategy Then you need to follow these 3 steps • The price has to be above the 50 EMA • The price has to be above the 200 EMA • The price should gap up in an uptrend This is the rocket booster strategy In order to learn more Rocket boost this content Disclaimer:Trading is risky you will lose money so please use a simulation trading account before you trade with real money.Also learn Risk management and profit taking strategies.
NASDAQ:AMZNLong
by lubosi
Force motors - deep in wave 5. book profitsForce motors looks like deep into wave 5 Book profits. Once it turns a medium term top should be in
NSE:FORCEMOTShort
by yossarian121
OFSS IDEALooking into a good shape compressing inside triangular formation.
NSE:OFSSLong
by rustyjonesofc
CE INFO SYSTEMS LTD S/RSupport and Resistance Levels: Support Levels: These are price points (green line/shade) where a downward trend may be halted due to a concentration of buying interest. Imagine them as a safety net where buyers step in, preventing further decline. Resistance Levels: Conversely, resistance levels (red line/shade) are where upward trends might stall due to increased selling interest. They act like a ceiling where sellers come in to push prices down. Breakouts: Bullish Breakout: When the price moves above resistance, it often indicates strong buying interest and the potential for a continued uptrend. Traders may view this as a signal to buy or hold. Bearish Breakout: When the price falls below support, it can signal strong selling interest and the potential for a continued downtrend. Traders might see this as a cue to sell or avoid buying. MA Ribbon (EMA 20, EMA 50, EMA 100, EMA 200) : Above EMA: If the stock price is above the EMA, it suggests a potential uptrend or bullish momentum. Below EMA: If the stock price is below the EMA, it indicates a potential downtrend or bearish momentum. Trendline: A trendline is a straight line drawn on a chart to represent the general direction of a data point set. Uptrend Line: Drawn by connecting the lows in an upward trend. Indicates that the price is moving higher over time. Acts as a support level, where prices tend to bounce upward. Downtrend Line: Drawn by connecting the highs in a downward trend. Indicates that the price is moving lower over time. It acts as a resistance level, where prices tend to drop. Disclaimer: I am not a SEBI registered. The information provided here is for learning purposes only and should not be interpreted as financial advice. Consider the broader market context and consult with a qualified financial advisor before making investment decisions.
NSE:MAPMYINDIA
by zenthosh
ABFRLIs the financial engineering dead ? Have a look at most of the demergers, they are short term euphoria. ABFRL is no less. The Consultants take their million dollar fees for their MBA jargon / useless and non practical solutions and billions of dollars of losses for the shareholders. Technically ABFRL could have a bounce back at Rs 77 but could consolidate here for a few months before trying to ascend.
NSE:ABFRL
by SWFguy
112233445566778899101011111212131314141515161617171818191920202121222223232424252526262727282829293030313132323333343435353636373738383939404041414242
…999999

Select market data provided by ICE Data services. Select reference data provided by FactSet. Copyright © 2025 FactSet Research Systems Inc.© 2025 TradingView, Inc.

More than a product
  • Supercharts
Screeners
  • Stocks
  • ETFs
  • Bonds
  • Crypto coins
  • Crypto pairs
  • CEX pairs
  • DEX pairs
  • Pine
Heatmaps
  • Stocks
  • ETFs
  • Crypto
Calendars
  • Economic
  • Earnings
  • Dividends
More products
  • Yield curves
  • Options
  • News Flow
  • Pine Script®
Apps
  • Mobile
  • Desktop
Community
  • Social network
  • Wall of Love
  • Refer a friend
  • House Rules
  • Moderators
Ideas
  • Trading
  • Education
  • Editors' picks
Pine Script
  • Indicators & strategies
  • Wizards
  • Freelancers
Tools & subscriptions
  • Features
  • Pricing
  • Market data
Trading
  • Overview
  • Brokers
Special offers
  • CME Group futures
  • Eurex futures
  • US stocks bundle
About company
  • Who we are
  • Manifesto
  • Athletes
  • Blog
  • Careers
  • Media kit
Merch
  • TradingView store
  • Tarot cards for traders
  • The C63 TradeTime
Policies & security
  • Terms of Use
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Accessibility Statement
  • Security vulnerability
  • Status page
Business solutions
  • Widgets
  • Charting libraries
  • Lightweight Charts™
  • Advanced Charts
  • Trading Platform
Growth opportunities
  • Advertising
  • Brokerage integration
  • Partner program
  • Education program
Community
  • Social network
  • Wall of Love
  • Refer a friend
  • House Rules
  • Moderators
Ideas
  • Trading
  • Education
  • Editors' picks
Pine Script
  • Indicators & strategies
  • Wizards
  • Freelancers
Business solutions
  • Widgets
  • Charting libraries
  • Lightweight Charts™
  • Advanced Charts
  • Trading Platform
Growth opportunities
  • Advertising
  • Brokerage integration
  • Partner program
  • Education program
Look FirstLook First